Long-term safety of continuous levodopa/carbidopa infusion with ND0612: Results from the ongoing BeyoND study
MOVEMENT DISORDERS(2022)
摘要
Background:ND0612 is in development as a continuous, subcutaneous levodopa/carbidopa (LD/CD) delivery system for Parkinson’s disease (PD) experiencing motor fluctuations. Primary safety data from the BeyoND study (NCT02726386) showed that subcutaneous LD/CD infusion with ND0612 is generally safe up to one year of treatment. The study has been extended to 102 months, and we report cumulative data beyond the first year of treatment.
更多查看译文
关键词
levodopa/carbidopa infusion,continuous levodopa/carbidopa,long-term
AI 理解论文
溯源树
样例
![](https://originalfileserver.aminer.cn/sys/aminer/pubs/mrt_preview.jpeg)
生成溯源树,研究论文发展脉络
Chat Paper
正在生成论文摘要